首页> 美国卫生研究院文献>Marine Drugs >Kororamides Convolutamines and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer’s Disease: A Computational Study
【2h】

Kororamides Convolutamines and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer’s Disease: A Computational Study

机译:Kororamidesconvolutamines和吲哚衍生物可能是Tau和双特异性激酶抑制剂对阿尔茨海默氏病的影响:一项计算研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) is becoming one of the most disturbing health and socioeconomic problems nowadays, as it is a neurodegenerative pathology with no treatment, which is expected to grow further due to population ageing. Actual treatments for AD produce only a modest amelioration of symptoms, although there is a constant ongoing research of new therapeutic strategies oriented to improve the amelioration of the symptoms, and even to completely cure the disease. A principal feature of AD is the presence of neurofibrillary tangles (NFT) induced by the aberrant phosphorylation of the microtubule-associated protein tau in the brains of affected individuals. Glycogen synthetase kinase-3 beta (GSK3β), casein kinase 1 delta (CK1δ), dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) and dual-specificity kinase cdc2-like kinase 1 (CLK1) have been identified as the principal proteins involved in this process. Due to this, the inhibition of these kinases has been proposed as a plausible therapeutic strategy to fight AD. In this study, we tested in silico the inhibitory activity of different marine natural compounds, as well as newly-designed molecules from some of them, over the mentioned protein kinases, finding some new possible inhibitors with potential therapeutic application.
机译:阿尔茨海默氏病(AD)成为当今最令人不安的健康和社会经济问题之一,因为它是一种未经治疗的神经退行性病变,随着人口老龄化,这种疾病有望进一步发展。尽管有持续不断的针对旨在改善症状改善甚至完全治愈疾病的新治疗策略的研究,AD的实际治疗只能产生适度的症状改善。 AD的主要特征是在受影响的个体的大脑中存在由微管相关蛋白tau的异常磷酸化诱导的神经原纤维缠结(NFT)。糖原合成酶激酶3β(GSK3β),酪蛋白激酶1δ(CK1δ),双特异性酪氨酸磷酸化调节激酶1A(DYRK1A)和双特异性激酶cdc2样激酶1(CLK1)已被确定为主要蛋白在这个过程中。因此,已经提出抑制这些激酶作为对抗AD的可行治疗策略。在这项研究中,我们在计算机上测试了不同的海洋天然化合物以及其中一些新设计的分子对上述蛋白激酶的抑制活性,发现了一些可能具有潜在治疗应用的新抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号